Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects.

Pharmacotherapy
Scott R PenzakJoseph A Kovacs

Abstract

. To determine the influence of Echinacea purpurea on the pharmacokinetics of lopinavir-ritonavir and on cytochrome P450 (CYP) 3A and P-glycoprotein activity by using the probe substrates midazolam and fexofenadine, respectively. Open-label, single-sequence pharmacokinetic study. Outpatient clinic in a federal government research center. Thirteen healthy volunteers (eight men, five women). Subjects received lopinavir 400 mg-ritonavir 100 mg twice/day with meals for 29.5 days. On day 16, subjects received E. purpurea 500 mg 3 times/day for 28 days: 14 days in combination with lopinavir-ritonavir and 14 days of E. purpurea alone. In order to assess CYP3A and P-glycoprotein activity, subjects received single oral doses of midazolam 8 mg and fexofenadine 120 mg, respectively, before and after the 28 days of E. purpurea. On days 15 and 30 of lopinavir-ritonavir administration (before and after E. purpurea administration, respectively), serial blood samples were collected over 12 hours to determine lopinavir and ritonavir concentrations and subsequent pharmacokinetic parameters by using noncompartmental methods. Neither lopinavir nor ritonavir pharmacokinetics were significantly altered by 14 days of E. purpurea coadministration. The...Continue Reading

References

Feb 22, 2000·Lancet·S C PiscitelliJ Falloon
Sep 2, 2000·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·J W BudzinskiJ T Arnason
Dec 12, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stephen C PiscitelliJudith Falloon
Jun 10, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·An-Fu HsiaoUNKNOWN HCSUS Consortium
Jan 30, 2004·Clinical Pharmacology and Therapeutics·J Christopher GorskiStephen D Hall
Jul 13, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Michael L LimAngela D M Kashuba
Apr 28, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Alyson L HuntleyEdzard Ernst
Jul 5, 2005·The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy·Steven H Yale, Ingrid Glurich
Jan 22, 2008·Current Medical Research and Opinion·Sarah M RobertsonScott R Penzak
Aug 9, 2008·Phytotherapy Research : PTR·Torstein Schrøder Hansen, Odd Georg Nilsen
Sep 30, 2009·British Journal of Pharmacology·A Kalliokoski, M Niemi
Oct 10, 2009·Integrative Cancer Therapies·Stacy S ShordAlvina Lukose

❮ Previous
Next ❯

Citations

Jul 3, 2013·Nature Reviews. Gastroenterology & Hepatology·Jennifer J KiserGregory T Everson
Aug 8, 2012·Antimicrobial Agents and Chemotherapy·José MoltóBonaventura Clotet
Jan 20, 2012·Clinical Pharmacokinetics·Shaojun Shi, Ulrich Klotz
Dec 20, 2012·Expert Review of Molecular Diagnostics·Miao HuBrian Tomlinson
Jan 7, 2014·Expert Opinion on Drug Metabolism & Toxicology·Walter Emil Haefeli, Alexandra Carls
Oct 18, 2016·Journal of Ginseng Research·Dal-Sik KimMin-Gul Kim
Feb 15, 2011·Heart, Lung & Circulation·Lesley A Braun, Marc Cohen
Jun 18, 2010·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de Expertos de Gesida, UNKNOWN Plan Nacional sobre el Sida
May 25, 2013·British Journal of Clinical Pharmacology·Andrew K L GoeyJan H M Schellens
Jun 8, 2011·Journal of Clinical Pharmacology·Christine Y MalatiScott R Penzak
Aug 28, 2015·European Journal of Drug Metabolism and Pharmacokinetics·Enoche F OgaToshiharu Horie
Nov 8, 2014·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Charles AwortweBernd Rosenkranz
Oct 8, 2016·Expert Review of Clinical Pharmacology·Kristina M BrooksParag Kumar
Sep 23, 2016·International Journal of STD & AIDS·Mohamed A JallohAleah Rodriguez
Jan 25, 2018·British Journal of Clinical Pharmacology·Charles AwortweBernd Rosenkranz
Mar 14, 2012·British Journal of Hospital Medicine·Mohammed LamordeConcepta Merry
Oct 11, 2017·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Charles AwortweHenrike Bruckmueller
Mar 10, 2016·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Nuggehally R Srinivas
Aug 29, 2017·BioMed Research International·C M LopesR Oliveira
Jun 3, 2018·European Journal of Drug Metabolism and Pharmacokinetics·Lilian W KibathiParag Kumar
May 3, 2019·Integrative Cancer Therapies·Loisa DrozdoffDaniela Paepke
May 4, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C BordesP Loubet
Oct 29, 2020·Archives of Toxicology·Jukka HakkolaOlavi Pelkonen
Mar 18, 2021·Molecular Pharmaceutics·Charles AwortweIngolf Cascorbi
Jul 6, 2019·Critical Reviews in Oncology/hematology·Paul GougisRomain Coriat
May 1, 2021·Critical Reviews in Oncology/hematology·Paul GougisChristian Funck-Brentano
Nov 5, 2021·Irish Journal of Medical Science·Janelle M MaturaVictoria A Bankes

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.